Loading patent…
AssigneeOncotherapy Science, Inc.
InventorsYusuke Nakamura, Takuya Tsunoda, Ryuji Osawa, Sachiko Yoshimura, Tomohisa Watanabe, Gaku Nakayama
Estimating the term…
The present invention provides isolated epitope peptides derived from TOPK and immunogenic fragments thereof have an ability to induce cytotoxic T lymphocytes (CTLs) and thus are suitable for use in cancer immunotherapy, more particularly as cancer vaccines. The peptides of the present invention encompass both of peptides including a TOPK-derived amino acid sequence and modified versions thereof, in which one, two, or several amino acids are substituted, deleted, inserted and/or added, provided such modified versions have CTL inducibility. Further provided are polynucleotides encoding any of the aforementioned peptides as well as pharmaceutical compositions that include any of the aforementioned peptides or polynucleotides. The peptides, polynucleotides, and pharmaceutical compositions of this invention find particular utility in either or both of the treatment and prevention of a number of cancers.
A method of inducing an immune response against cancer in a subject, said method comprising the step of administering to the subject a composition comprising an isolated peptide of less than 15 amino acid(s), or a polynucleotide encoding the peptide, wherein the peptide is selected from the group consisting of (a)-(d) below:
Dependencies are inferred from the claim text.